The national Minister of Health and provincial MECs for Health limited the availability of the antiretroviral drug nevirapine, used to prevent mother-to-child transmission (MTCT) of HIV, to a small number of pilot research sites in the public health sector. Nevirapine was registered as safe and effective, approved for MTCT prevention, and offered to the government free of charge for five years. Doctors in the private sector could prescribe it, but public-sector doctors outside pilot sites were prohibited from doing so. Civil society organisations, led by the Treatment Action Campaign (TAC), challenged this policy, arguing that it violated constitutional rights to access health care services (section 27) and children’s rights to basic health care services (section 28), and that government had failed to implement a comprehensive national programme to prevent MTCT of HIV.